{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T17:53:52Z","timestamp":1777312432776,"version":"3.51.4"},"reference-count":46,"publisher":"Hamad bin Khalifa University Press (HBKU Press)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"abstract":"\n Background:<\/jats:bold>\n Despite substantial clinical evidence and recommendations from international societies supporting the use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for managing patients with type-2 diabetes (T2D) and chronic kidney disease (CKD), their adoption has remained limited. To address this, the nephrology quality improvement (QI) team at Hamad Medical Corporation (HMC), Qatar, implemented a key performance indicator (KPI) program in March 2022, aiming to ensure that at least 80% of eligible T2D-CKD patients at HMC were receiving SGLT2i by December 31, 2023.\n <\/jats:p>\n \n Methods:<\/jats:bold>\n The use of SGLT2i and angiotensin-converting enzyme inhibitor (ACEi) or angiotensin II receptor blocker (ARB) in T2D-CKD patients attending nephrology clinics at HMC hospitals were assessed through retrospective surveys using a cluster-based sampling approach. Nephrology physicians were then updated on the results of these retrospective surveys as well as evidence from the SGLT2i trial and guidelines. The aims, objectives, and targets of the KPI program were clearly defined. Three additional surveys were conducted at 6-month intervals. A multifaceted QI intervention approach\u2014combining audit, feedback, leadership engagement, and peer consultation\u2014was implemented to drive improvement.\n <\/jats:p>\n \n Results:<\/jats:bold>\n Retrospective surveys conducted in November 2021 and February 2022 revealed that 38% and 44% of eligible T2D-CKD patients were receiving SGLT2i therapy, compared to 98% and 99% for ACEi\/ARB. Four months after implementing the KPI program, the July 2022 survey revealed no change in SGLT2i use (41%), while ACEi\/ARB prescription rates remained near 100%. Following QI interventions in November 2022, the February 2023 survey revealed a significant increase in SGLT2i use, rising to 88%, with SGLT2i initiation in naive patients increasing from 34% to 61%. The final survey conducted in August 2023 showed that 84% of patients were receiving SGLT2i therapy.\n <\/jats:p>\n \n Conclusion:<\/jats:bold>\n Our KPI program boosted SGLT2i prescription rates for eligible T2D-CKD patients in nephrology clinics, resulting in a 47% rise from 41% to 88%. It overcame prescription inertia and accelerated the guideline adoption by combining real-time feedback, leadership engagement, and peer discussions. The sharp rise in new prescriptions following November 2022 feedback underscores its direct influence on behavior modification rather than a broader trend.\n <\/jats:p>","DOI":"10.5339\/qmj.2025.50","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T11:30:47Z","timestamp":1752579047000},"source":"Crossref","is-referenced-by-count":0,"title":["Enhancing the use of sodium-glucose cotransporter-2 inhibitors in type-2 diabetic patients with chronic kidney disease, through a key performance indicator program"],"prefix":"10.5339","volume":"2025","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3180-1671","authenticated-orcid":true,"given":"Muhammad","family":"Asim","sequence":"first","affiliation":[{"name":"Department of Medicine, Hamad General Hospital, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramzi","family":"Abdul Rahiman","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation, Doha, Qatar*Correspondence: Muhammad Asim masim@hamad.qa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Abdul Azim Baig","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation, Doha, Qatar*Correspondence: Muhammad Asim masim@hamad.qa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan","family":"Al-Malki","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation, Doha, Qatar*Correspondence: Muhammad Asim masim@hamad.qa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3277","reference":[{"issue":"(24):","key":"CIT0001","series-title":"N Engl J Med","first-page":"2295\u2013306","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic\n \nV","year":"2019;"},{"issue":"(11):","key":"CIT0002","series-title":"Circulation","first-page":"1384\u201395","article-title":"Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial","volume":"139","author":"Fitchett\n \nD","year":"2019;"},{"issue":"(15):","key":"CIT0003","series-title":"N Engl J Med","first-page":"1436\u201346","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink\n \nHJL","year":"2020;"},{"issue":"(5S):","key":"CIT0004","series-title":"Kidney Int","first-page":"S1\u201327","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2022;"},{"issue":"(12):","key":"CIT0005","series-title":"Diabetes Care","first-page":"3075\u201390","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"45","author":"de Boer\n \nIH","year":"2022;"},{"issue":"(1):","key":"CIT0006","series-title":"Sci Rep","first-page":"5969","article-title":"Integrated analysis for treatment scheme of sodium-glucose cotransporter 2 inhibitors in patients with diabetic kidney disease: a real-world study","volume":"13","author":"Fang\n \nL","year":"2023;"},{"issue":"(8):","key":"CIT0007","series-title":"health systems. J Am Coll Cardiol","first-page":"683\u201393","article-title":"Prescription patterns for sodium-glucose cotransporter 2 inhibitors in U.S","volume":"84","author":"Shin\n \nJI","year":"2024;"},{"key":"CIT0008","author":"Hamad Medical Corporation","year":"c2024"},{"key":"CIT0009","article-title":"Johns Hopkins University School of Medicine calculator"},{"key":"CIT0010","series-title":"BMJ","first-page":"828","article-title":"Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review","volume":"329","author":"Strippoli\n \nGF","year":"2004;"},{"issue":"(3):","key":"CIT0011","series-title":"Diabetologia","first-page":"566\u201378","article-title":"Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis","volume":"55","author":"Vejakama\n \nP","year":"2012;"},{"issue":"(1):","key":"CIT0012","series-title":"Cardiovasc Diabetol","first-page":"185","article-title":"Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes","volume":"19","author":"Schernthaner\n \nG","year":"2020;"},{"issue":"(9):","key":"CIT0013","series-title":"Kidney Int Rep","first-page":"2059\u201370","article-title":"Low adherence to Kidney Disease: Improving Global Outcomes 2012 CKD Clinical Practice Guidelines despite clear evidence of utility","volume":"7","author":"James\n \nG","year":"2022;"},{"key":"CIT0014","series-title":"Patient Prefer Adherence","first-page":"2667\u201380","article-title":"Adherence to ADA clinical guidelines in type 2 diabetes management in public health clinics in Palestine","volume":"18","author":"Abukhalil\n \nAD","year":"2024;"},{"issue":"(5):","key":"CIT0015","series-title":"Cureus","first-page":"e38676","article-title":"Underutilization of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in diabetic nephropathy patients in government-run hospitals in India","volume":"15","author":"Maradia\n \nJ","year":"2023;"},{"key":"CIT0016","series-title":"Can J Kidney Health Dis","first-page":"20543581231217857","article-title":"Identifying barriers and facilitators for increasing uptake of sodium-glucose cotransporter-2 (SGLT2) inhibitors in British Columbia, Canada, using the Consolidated Framework for Implementation Research","volume":"11","author":"Yi\n \nTW","year":"2023;"},{"issue":"(10):","key":"CIT0017","series-title":"PLoS One","first-page":"e0204826","article-title":"Influence of peer networks on physician adoption of new drugs","volume":"13","author":"Donohue\n \nJM","year":"2018;"},{"issue":"(6):","key":"CIT0018","series-title":"Ethiop J Health Sci","first-page":"795\u2013804","article-title":"Factors influencing prescribing decisions of physicians: a review","volume":"28","author":"Davari\n \nM","year":"2018;"},{"issue":"(8883):","key":"CIT0019","series-title":"Lancet","first-page":"1317\u201322","article-title":"Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations","volume":"342","author":"Grimshaw\n \nJM","year":"1993;"},{"issue":"(2 Suppl):","key":"CIT0020","series-title":"Chest","first-page":"40S\u20136S","article-title":"Organizational interventions to encourage guideline implementation","volume":"118","author":"Curry\n \nSJ","year":"2000;"},{"issue":"(4):","key":"CIT0021","series-title":"Aust J Physiother","first-page":"233\u201341","article-title":"Multifaceted strategies may increase implementation of physiotherapy clinical guidelines: a systematic review","volume":"54","author":"Van der Wees\n \nPJ","year":"2008;"},{"issue":"(5):","key":"CIT0022","series-title":"Obstet Gynecol","first-page":"1234\u201345","article-title":"Evidence-based strategies for implementing guidelines in obstetrics: a systematic review","volume":"108","author":"Chaillet\n \nN","year":"2006;"},{"issue":"(8):","key":"CIT0023","series-title":"J Am Coll Cardiol","first-page":"1076\u201392","article-title":"ACC\/AHA special report: clinical practice guideline implementation strategies: a summary of systematic reviews by the NHLBI implementation science work group","volume":"69","author":"Chan\n \nWV","year":"2017;"},{"issue":"(24):","key":"CIT0001","series-title":"N Engl J Med","first-page":"2295\u2013306","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic\n \nV","year":"2019;"},{"issue":"(11):","key":"CIT0002","series-title":"Circulation","first-page":"1384\u201395","article-title":"Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial","volume":"139","author":"Fitchett\n \nD","year":"2019;"},{"issue":"(15):","key":"CIT0003","series-title":"N Engl J Med","first-page":"1436\u201346","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink\n \nHJL","year":"2020;"},{"issue":"(5S):","key":"CIT0004","series-title":"Kidney Int","first-page":"S1\u201327","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2022;"},{"issue":"(12):","key":"CIT0005","series-title":"Diabetes Care","first-page":"3075\u201390","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"45","author":"de Boer\n \nIH","year":"2022;"},{"issue":"(1):","key":"CIT0006","series-title":"Sci Rep","first-page":"5969","article-title":"Integrated analysis for treatment scheme of sodium-glucose cotransporter 2 inhibitors in patients with diabetic kidney disease: a real-world study","volume":"13","author":"Fang\n \nL","year":"2023;"},{"issue":"(8):","key":"CIT0007","series-title":"health systems. J Am Coll Cardiol","first-page":"683\u201393","article-title":"Prescription patterns for sodium-glucose cotransporter 2 inhibitors in U.S","volume":"84","author":"Shin\n \nJI","year":"2024;"},{"key":"CIT0008","author":"Hamad Medical Corporation","year":"c2024"},{"key":"CIT0009","article-title":"Johns Hopkins University School of Medicine calculator"},{"key":"CIT0010","series-title":"BMJ","first-page":"828","article-title":"Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review","volume":"329","author":"Strippoli\n \nGF","year":"2004;"},{"issue":"(3):","key":"CIT0011","series-title":"Diabetologia","first-page":"566\u201378","article-title":"Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis","volume":"55","author":"Vejakama\n \nP","year":"2012;"},{"issue":"(1):","key":"CIT0012","series-title":"Cardiovasc Diabetol","first-page":"185","article-title":"Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes","volume":"19","author":"Schernthaner\n \nG","year":"2020;"},{"issue":"(9):","key":"CIT0013","series-title":"Kidney Int Rep","first-page":"2059\u201370","article-title":"Low adherence to Kidney Disease: Improving Global Outcomes 2012 CKD Clinical Practice Guidelines despite clear evidence of utility","volume":"7","author":"James\n \nG","year":"2022;"},{"key":"CIT0014","series-title":"Patient Prefer Adherence","first-page":"2667\u201380","article-title":"Adherence to ADA clinical guidelines in type 2 diabetes management in public health clinics in Palestine","volume":"18","author":"Abukhalil\n \nAD","year":"2024;"},{"issue":"(5):","key":"CIT0015","series-title":"Cureus","first-page":"e38676","article-title":"Underutilization of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in diabetic nephropathy patients in government-run hospitals in India","volume":"15","author":"Maradia\n \nJ","year":"2023;"},{"key":"CIT0016","series-title":"Can J Kidney Health Dis","first-page":"20543581231217857","article-title":"Identifying barriers and facilitators for increasing uptake of sodium-glucose cotransporter-2 (SGLT2) inhibitors in British Columbia, Canada, using the Consolidated Framework for Implementation Research","volume":"11","author":"Yi\n \nTW","year":"2023;"},{"issue":"(10):","key":"CIT0017","series-title":"PLoS One","first-page":"e0204826","article-title":"Influence of peer networks on physician adoption of new drugs","volume":"13","author":"Donohue\n \nJM","year":"2018;"},{"issue":"(6):","key":"CIT0018","series-title":"Ethiop J Health Sci","first-page":"795\u2013804","article-title":"Factors influencing prescribing decisions of physicians: a review","volume":"28","author":"Davari\n \nM","year":"2018;"},{"issue":"(8883):","key":"CIT0019","series-title":"Lancet","first-page":"1317\u201322","article-title":"Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations","volume":"342","author":"Grimshaw\n \nJM","year":"1993;"},{"issue":"(2 Suppl):","key":"CIT0020","series-title":"Chest","first-page":"40S\u20136S","article-title":"Organizational interventions to encourage guideline implementation","volume":"118","author":"Curry\n \nSJ","year":"2000;"},{"issue":"(4):","key":"CIT0021","series-title":"Aust J Physiother","first-page":"233\u201341","article-title":"Multifaceted strategies may increase implementation of physiotherapy clinical guidelines: a systematic review","volume":"54","author":"Van der Wees\n \nPJ","year":"2008;"},{"issue":"(5):","key":"CIT0022","series-title":"Obstet Gynecol","first-page":"1234\u201345","article-title":"Evidence-based strategies for implementing guidelines in obstetrics: a systematic review","volume":"108","author":"Chaillet\n \nN","year":"2006;"},{"issue":"(8):","key":"CIT0023","series-title":"J Am Coll Cardiol","first-page":"1076\u201392","article-title":"ACC\/AHA special report: clinical practice guideline implementation strategies: a summary of systematic reviews by the NHLBI implementation science work group","volume":"69","author":"Chan\n \nWV","year":"2017;"}],"container-title":["Qatar Medical Journal"],"original-title":[],"link":[{"URL":"https:\/\/www.qscience.com\/view\/journals\/qmj\/2025\/2\/article-50.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.qscience.com\/downloadpdf\/journals\/qmj\/2025\/2\/article-50.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.qscience.com\/downloadpdf\/journals\/qmj\/2025\/2\/article-50.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T17:17:27Z","timestamp":1777310247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.qscience.com\/view\/journals\/qmj\/2025\/2\/article-50.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":46,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.5339\/qmj.2025.50","relation":{},"ISSN":["2227-0426"],"issn-type":[{"value":"2227-0426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}